Anzeige
Mehr »
Lynx Broker
Login
Montag, 19.08.2019 Börsentäglich über 12.000 News von 605 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Zur alten Webversion

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrAbbVie scores blockbuster approval for RA med Rinvoq, its crucial Humira followup
FrIn a boon for buyer Bristol-Myers, Celgene's JAK med Inrebic scores FDA nod
FrInvestors angry about insulin woes sue Novo Nordisk in Denmark for $1.75B
FrDebt-laden Glenmark counts on assets sales, spinoffs to dig it out
FrAnother hit for Roche: UnitedHealthcare backs Amgen biosims over blockbuster oncology meds
FrBausch may have shed the Valeant name, but it still leans on price hikes: analyst
FrFiercePharmaAsia-Lowest-paid Indian pharma CEO; Dr. Reddy's CRL; Natco's double whammy
FrRoche scores double cancer approval for new Bayer rival Rozlytrek
DoSanofi defends top oncology drug with Jevtana patent win
DoTop 10 all-star drugs in 2024: Humira's captain, but who else makes the roster?
DoTeva shares approach 20-year low amid Moody's warning and other woes
DoPfizer recalls migraine med Relpax because of bacteria contamination
DoEmcure knocked by the FDA for sterility issues after injectable drug recall
DoFDA cites solvent recovery firm as a player in the valsartan mess
DoHarmony Biosciences scores first approval in narcolepsy med Wakix
MiNovartis' AveXis shifted top scientific leadership before Zolgensma data scandal erupted
MiRegeneron plots $800M New York production push-along with 1,500 new jobs
MiAllergan CEO Saunders lines up for $39M payout after AbbVie buy
MiAstraZeneca, Merck's latest Lynparza combo win could widen its ovarian cancer reach
MiLawmakers to Teva and Mylan: Stop stonewalling our price-fixing probe
MiDr. Reddy's Copaxone, NuvaRing generics derailed by FDA
MiDoes Stada need Takeda's for-sale European drugs? CEO says no
DiTable for two: AbbVie was Allergan's only suitor in $63B takeover that shocked the industry
DiNovartis names Bulto new U.S. pharma chief as exec reshuffle continues
DiEli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt